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The therapeutic potential of 131I-Lipiodol was investigated in 8 patients with cholangiocarcinoma (CCA)
and 15 patients with hepatocellullar carcinoma (HCC). Patients received one or two doses of
131I-Lipiodol via hepatic arterial injection. The mean total administered activity was 668 (SD 325) MBq
in CCA and 953 (SD 477) MBq in HCC. One patient with CCA retained 13q-Lipiodol. The cumulative
radiation dose was 9.6 Gy to tumour, 6.4 Gy to liver and 1.5 Gy to lung. The patient remained
asymptomatic with no evidence of tumour 30 months from the start of treatment, whereas the remaining
7 patients exhibited tumour progression. The mean survival in CCA was 11.6 (SD 14.5) months. All 15
patients with HCC retained 131I with tumour: liver ratios of up to 30:1. The mean cumulative radiation
dose was 34.7 (SD 32.4) Gy to tumour, 3.3 (SD 1.5) Gy to liver and 4.4 (SD 2.3) Gy to lung. The mean
dose per administered activity was 3.8 (SD 4.1) cGy/MBq. Partial response (reduction in tumour size >
50%) was observed in 6 patients (40%). The mean survival was 7.1 (SD 6.0) months.
131I-Lipiodol can deliver highly selective internal irradiation to foci ofHCC with evidence of objective
response and may be the treatment of choice for patients with cirrhosis and a small tumour.
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INTRODUCTION
Lipiodol (Lipiodol Ultra Fluid, May & Baker, England) is a lipid derived from
poppyseed oil. It contains 475mg of iodine per ml (38% by weight) and has been
used for many years as a contrast medium, principally in lymphography. In 1979
Nakakuma et al. injected Lipiodol into the hepatic artery and demonstrated its
selective retention in loci of hepatocellular carcinoma1. Using a simple exchange
reaction2, part of the iodine component of Lipiodol may be replaced by the
radioactive isotope 131I, making it an ideal vehicle for the delivery of internal
131 radiotherapy, I-Lipiodol has been studied using scintigraphy in human subjects
and exhibits a similar pattern of uptake and retention to the non-radioactive
lipid3-6. Tsai et al. have measured the uptake of 131I-Lipiodol in an animal tumour
model and have shown it to have a significantly longer effective half life in tumour
than in normal tissue, resulting in almost complete necrosis of the tumour7.
Toxicity to thyroid, bone marrow or lung has not been reported.
This paper is based on a presentation to the 4th World Congress of HPB Surgery in Hong Kong, June
1992.
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Previous authors have reported promising results using 131I-Lipiodol in hepato-
cellular carcinoma (HCC), with tumour shrinkage and symptomatic improvement
in the majority of patients5’8. Response has been reported to be greatest in small
loci ofHCC without significant vascular shunting9. In a prospective analysis of fifty
patients with Stage I and II HCC by Le Jeune et al. the overall survival at 6 months,
12 months and 2 years was 60%, 31% and 23% respectively1. Initial studies have
shown 1311 retention in small colorectal metastases, but localisation in larger
deposits is very pooru.
Our earlier studies on Lipiodol-targeted chemotherapy
12 showed no evidence of
response in the tumours studied, although survival in Stage I and IIHCC was better
than expected. They did, however, demonstrate excellent deposition and retention
of Lipiodol in HCC, particularly smaller tumour loci. The aim of this study was to
investigate the therapeutic potential of 13q-Lipiodol in two histological variants of
primary liver cancer.
PATIENTS, MATERIALS AND METHODS
Patients
Inclusion criteria for the trial were unresectable cholangiocarcinoma or hepatocel-
lular carcinoma.
Cholangiocarcinoma (CCA)
All patients had unresectable intrahepatic or hilar tumours. Exclusion criteria were
as follows:
Patients older than 75 yrs.
Serious concurrent medical conditions.
WHO Performance Grade > 2
Haemoglobin < 10 g/dl.
Severe clotting abnormalities.
Hepatic failure.
Extrahepatic metastases.
The treated group comprised eight patients with a median age of 56 years (range
44-62 years). There were five males and three females. Histological proof of the
diagnosis was obtained in six patients; in the remaining two cases (Patient Nos. 04
& 07) endoscopic biopsy, biliary cytology and in one case open biopsy at laparo-
tomy were persistently negative. In these cases the diagnosis of CCA was estab-
lished on the basis of the following criteria:
(i) a discrete stricture of the hilar or intrahepatic bile ducts;
(ii) a corresponding low-attenuation area on CT which did not demonstrate
uniform vascular enhancement following intravenous injection of contrast media;
(iii) a hypovascular appearance on angiography, with or without vascular encase-
ment. Prior to 131-Lipiodol therapy all patients underwent percutaneous insertion of
a biliary endoprosthesis, with good symptomatic relief in all cases.RADIONUCLIDE LOCALISATION IN TUMOURS 187
Hepatocellular carcinoma (HCC)
Exclusion criteria were as for CCA, with the addition of Okuda Stage III tumours.
The treated patients with HCC comprised 14 caucasians and one negro. There were
13 men and 2 women, with a median age of 64 years (range 41-75 years). A
histological diagnosis of hepatocellular carcinoma was obtained in 13 patients. In
two patients with a negative biopsy (Patient Nos. 14 & 21) a hypervascular
appearance at angiography in combination with a raised serum alpha fetoprotein
(AFP) was regarded as diagnostic of HCC. In 12 patients the tumour occurred in a
cirrhotic liver; three patients had no clinical or histological evidence of cirrhosis,
including one with recurrent fibrolamellar HCC. Tumours were staged according to
the classification of Okuda13. Four patients had Stage I tumours at diagnosis
(including two with newly-diagnosed recurrence following hepatic resection) and 11
patients had Stage II tumours.
Technique
Seldinger catheterisation of the hepatic artery under fluoroscopic control was
performed via a femoral artery puncture. 15-40 mCi 131I-radiolabelled Lipiodol
(CIS Bioindustries, Saclay, France), was diluted to a total volume of 12ml with cold
Lipiodol using two sterile 20ml glass syringes and a 3-way tap with luer locks. This
volume of Lipiodol was administered by slow injection into the hepatic artery and
the system flushed with 20ml of normal saline. Firm pressure was applied to the
groin puncture site for 5 mins using a sterile lead-gloved hand.
All procedures were designed to keep radiation exposures to staff as low as
reasonably achievable. Catheterisations were performed at the end of a session in
the Angiography suite to allow time for decontamination should any spillage occur,
and only essential staff were present in the room during the procedure. Glass
syringes were employed throughout as Lipiodol has a solvent action on polystyr-
ene. Monitoring of both room and staff was carried out immediately following
completion of the procedure.
Routine clinical observations were carried out following angiography. Daily
haematological and liver indices were performed for the duration of the inpatient
stay. The treatment was repeated in patients who showed continued clinical
wellbeing and/or reduction in tumour size. The median administered activity was
600 MGq (range 300-1160 MBq) in CCA and 875 MBq (range 525-2055 MBq) in
HCC.
Tumour Assessment
All patients underwent 99Tc colloid liver scintigraphy prior to treatment for
comparison with later 1311 scintigraphy. To assess Lipiodol uptake and response to
treatment, a CT scan of the liver was performed at 10 days. Perpendicular
diameters were measured for each tumour focus. Tumour volumes were calculated
from the CT scan using the formula:
Volume maximum tumour diameter x perpendicular diameter
2
Tumour response was assessed on lesion size (determined on serial CT measure-
ments) and tumour marker levels. Patients were graded Complete Response (CR),188 J.R. NOVELL ET AL.
Partial Response (PR), No Change (NC) or Progressive Disease (PD) according to
WHO criteria14. Toxicity grading was also assessed on WHO criteria14. AFP levels
were measured at diagnosis and during treatment; they were within normal limits in
all patients with CCA.
Liver retention of the labelled lipid was assessed by scintigraphy at 24-48 hours
and 6-8 days using a Scintronix 480S Digicamera fitted with a high energy 1.9mm
hexagonal-holed plane collimator. Planar anterior and posterior images of the liver
and thorax were acquired over a five minute period and stored on floppy disk for
later analysis. The pattern of uptake was compared to the distribution of Lipiodol
within tumour tissue on synchronous CT scans of the liver and to 99Tc uptake on the
pre-treatment colloid scan. Using the acquired images, regions of interest were
drawn around the tumour, liver and lungs, and the total counts recorded for each
region. Counts were also recorded over an equivalent area of low activity distant
from the liver, and this "background" count subtracted from the tissue count in
each case.
Three patients with HCC were scanned on an IGE Gemini 700 camera fitted with
a 400KeV parallel-hole high resolution collimator, linked to a Saturn nuclear
medicine computer for data acquisition and image processing. IGE software was
used for tomographic image reconstruction and dosimetry. The doses of radioacti-
vity administered to the tumour, surrounding liver and lung were calculated using a
standard formulaeTM.
RESULTS
Cholangiocarcinoma
Localisation
Although prolonged retention of activity was observed in the peripheral liver
parenchyma in patients with hilar tumours, a comparison of the scintigraphic and
tomographic appearances 6-10 days after treatment showed no evidence of
tumour-selective retention of the radio-isotope in any patient. However, diffuse
retention was observed in one patient (Patient No. 07) who was reassessed 7 weeks
following treatment and found to retain focal activity in the hilar mass (Figure 1).
She has received a further course of 131I-Lipiodol and remains alive and well 30
months from the start of treatment. The cumulative radiation dose from two
treatments was calculated to be 9.6 Gy to tumour, 6.4 Gy to liver and 1.5 Gy to
lung.
Outcome
The clinical details and results of treatment in CCA are summarised in Table 1. The
median survival from 3q-Lipiodol treatment was 4.0 months (range 1.0-35.5
months). Five patients died from tumour progression within 4 months of treatment.
The longest surviving patient has also shown evidence of disease progression
clinically and has required readmission for recurrent obstructive jaundice, treated
by segment III hepatico-jejunostomy.RADIONUCLIDE LOCALISATION IN TUMOURS 189
Figure 1 Focal activity in hilar CCA at 7 weeks (AP gamma scan superimposed on colloid scan).
Hepatocellular Carcinoma
Localisation
Selective localisation of the isotope was demonstrated in all fifteen patients with
tumour: liver ratios of up to 30:1. The mean tumour: liver ratio was 9:1 (SD 8).
Although good localisation of the isotope was observed even in large, multifocal
deposits the highest tumour: liver ratios were seen in patients with small discrete
tumours. In one case tumour 1311 uptake was not confined to the liver. The patient
(No. 19), a 41 year old man with a massive central hepatoma, received a small
initial dose of isotope due to concern over poor liver function. Gamma imaging
showed localisation within the liver but also demonstrated a small mediastinal
nodule (Figure 2a). Five months later he remained well with no change in size of
the tumour on CT scan and a second larger dose was administered. On this190 J.R. NOVELL ET AL.
Table 1 Clinical details of patients receiving 3I-Lipiodol therapy for CCA
Pt. Age Sex Presenting Tumour Surgery Other
Symptoms Treatment
Activity Survival
1-131 (MBq) (mnths)
01 44 F RUQ pain Rt lobe/ Gastro-
Jaundice Hilar jejunostomy
02 55 M Hepatomegaly Hilar Laparotomy Mitomycin
Jaundice Mitozantrone
03 60 M RUQ pain Rt lobe/ Hepatodocho-
Jaundice Hilar jejunostomy
04 62 M Jaundice Hilar Segment III bypass
05 58 M RUQ pain Rt lobe/
Wt loss Hilar
06 57 F RUQ pain Hilar
Jaundice
07 54 F Wt loss Hilar/
Jaundice Lt lobe
08 53 M Jaundice Hilar
300 2.8
350 0.9
500 4.0
600 35.5
690 4.0
600 4.0
610 29.8
550
Hepatodocho- Radiotherapy 1140
jejunostomy 4800 cGy
occasion the 131I-Lipiodol was seen to localise in the thorax following intrahepatic
injection (Figure 2b). Imaging at 48 hours confirmed activity within the heart
(Figure 2c). Echocardiography subsequently confirmed a large tongue of turnout
extending from the hepatic veins to the right atrium.
The mean cumulative radiation dose was 34.7 (SD 32.4) Gy to tumour, 3.3 (SD
1.5) Gy to liver and 4.4 (SD 2.3) Gy to lung. The mean dose per administered
activity was 3.8 (SD 4.1) cGy/MBq (Table 2).
Outcome
Partial tumour response (PR) was seen in 6 patients (Table 3), with reduction in
tumour size > 50% in all 6 and reduction in serum AFP levels in two. No change
(NC) was observed in 4 patients and 4 patients had progressive disease (PD).
Patients exhibiting PD received a significantly lower mean tumour radiation dose
than patients with PR or NC (Figure 3, p 0.04, pooled estimate of variance).
17 As we have previously reported histological proof of response was obtained in
one patient (No. 10) with recurrent HCC. Good tumour localisation was observed
following 131I-Lipiodol administration (Figure 4a,b) and 3 months later a 5 cm
wedge of liver containing 2 discrete tumour nodules was resected. Histological
examination of the resected specimen showed both tumour nodules to be comple-
tely necrotic and surrounded by a zone of fibrotic but non-malignant parenchyma
(Figure 4c).
Five patients were alive and under regular follow-up at the end of the trial,
having survived 4-19 months from the start of treatment. Eight patients died, two
from widespread extrahepatic metastases and two from hepatic failure. Four
patients died from tumour progression: all had extensive multifocal disease which
had failed to respond to previous chemotherapy. Two patients were lost to follow-
up, one of whom was in remission at 16 months. Survival in HCC, calculated by
life-table analysis, was 61% at 6 months and 31% at 1 year (Figure 5). The medianRADIONUCLIDE LOCALISATION IN TUMOURS 191
(a)
(b)
(c)
Figure 2 Intracardiac localisation of 131I. (a) Activity in mediastinal nodule (AP gamma scan at 48
hours) (b) Supra-diaphragmatic focus of activity (Oblique lateral CXR at 1 hour) (c) Activity in heart
(AP gamma scan at 48 hours).192 J.R. NOVELL ET AL.
Table 2 Tissue Dosimetry in HCC
Pt Tumour Activity Tumour
No Volume (MBq) Dose
(cm3)
Liver
Dose
(cGy)
Lung T/L Dose/
Dose Ratio Activity
(cGy) (cGy) (cGy/MBq)
09 108 525 2068 199 266 10.4 3.9
10 15 475 7668 255 77 30.0 16.1
22 632 4132 232 109 17.8 6.5
11 422 740 1042 150 248 6.9 1.4
212 1315 3450 367 382 9.4 2.6
12 632 1164 1170 324 610 3.6 1.0
822 280 176 92 93 1.9 0.6
13 1255 601 579 322 222 1.8 1.0
14 29 713 3257 347 377 9.4 4.6
15 45 720 2657 226 441 11.8 3.7
16 436 800 713 262 405 2.7 0.9
136 992 365 372 91 1.0 0.4
17 38 961 2771 184 199 15.0 2.4
18 1200 875 1734 255 727 6.8 2.0
19 1200 247 40 102 66 0.4 0.2
20 934 800 500 350 696 1.4 0.6
21 72 743 4875 230 332 21.2 J7.6
742 3.2
22 250 885 7642 446 506 17.1 8.6
23 64 853 3687 198 757 18.6
1432 7.2
730 3.7 7.6
635 3.2
Table 3 Results of 131-I Lipiodol treatment in HCC
Pt Age Sex Stage Response Outcome
09 63 M II PR
10 70 F PR
11 75 M II PR
12 68 M II PD
13 69 M II PD
14 64 M PR
15 62 M II
16 42 F II PR
17 57 M II PR
18 65 M II PD
19 41 M II NC
20 75 M II PD
21 72 M II NC
22 50 M II NC
23 64 M NC
Died 3.0 months, bone 2
Lost to follow-up 16.2 months
Died 4.0 months, hepatorenal failure
Died 6.8 months, tumour progression
Died 1.1 months, tumour progression
Died 16.5 months, hepatic failure
Lost to follow-up
Alive 19.1 months
Died 10.7 months, tumour progression/bone 2
Died 3.6 months, tumour progression
Alive 5.2 months
Died 2.3 months, tumour progression
Alive 4.0 months
Alive 3.8 months
Alive 3.8 monthsRADIONUCLIDE LOCALISATION IN TUMOURS 193
Response vs Tumour
1311-Lipiodol Therapy
Dose
Mean Tumour Dose Gy
70
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10
0
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Figure 3 Radiation dose versus response in HCC.
survival was 4.0 months (range 1.1 19.1 months). The median survival by Okuda
stage was 16.2 months (range 3.8 16.5) for Stage I and 4.0 months (range 1.1
19.1) for Stage II tumours.
Adverse Effects
There were no complications associated with percutaneous catheterisation. No
significant activity was recorded in thyroid or bone marrow on whole body gamma
scintigraphy, and no patient developed thyroid insufficiency or haematological
evidence of marrow depression. In patients with small, discrete deposits of HCC
activity in the lung fields remained low following intrahepatic injection but in
patients with massive or multifocal tumours hepatopulmonary shunting of the
isotope was observed. The mean radiation dose to the lungs was less than 5 Gy and
no clinical signs of acute pneumonitis or chronic pulmonary fibrosis were observed
in any patient. Mild to moderate pyrexia (Grade 1-2) was seen following 13
treatments (45%). Mild to moderate elevation of liver transaminases and bilirubin
(Grade 1-2) occurred following 10 treatments (35%). Significant hepatotoxicity
occurred in one patient (No. 11), a 75 year old cirrhotic (Child-Pugh Grade B) who
developed hepatic encephalopathy and oliguria 2 days following a second treatment
x31 with I Lipiodol. The dose of radioactivity to tumour and non-neoplastic liver was
calculated to be 34.5 Gy and 3.7 Gy respectively. Liver ultrasound demonstrated
liquefaction of the tumour mass, and his deterioration in liver function was ascribed
to massive tumour necrosis. He was resuscitated and showed a slow but progressive
improvement in hepatorenal function. A further decline in his condition was
associated with episodes of sepsis, and he died one month following the treatment.194 J. R. NOVELL ET AL.
(a)
(b)
Figure 4 Response in HCC. (a) Uptake defect due to turnout in left hepatic lobe (AP colloid scan) (b)
131I uptake by turnout (AP gamma scan at 48 hours) (c) Light micrograph (reticulin stain) showing zone
fibrosis surrounding necrotic tumour nodule.RADIONUCLIDE LOCALISATION IN TUMOURS 195
Figure 4 (continued) (c)
Survival in HCC
131-1 Lipiodol therapy
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Figure 5 Survival in HCC following 131I-Lipiodol therapy.
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DISCUSSION
Results in CCA were disappointing, with only one of eight patients demonstrating
limited retention of activity in the region of the biliary obstruction on gamma
scintigraphy. Despite a relatively small radiation dose of approximately 1000 cGy
this patient survived for 30 months with no evidence of progression of her disease.
She required two hospital admissions for stent replacement during the follow-up
period but is currently asymptomatic with no indwelling stents and no evidence of
residual disease on CT scan.
To date there has been only one report on the use of 131I-Lipiodol in a case of
intrahepatic cholangiocarcinomalS: no selective retention of the radio-isotope
occurred. Targeted chemotherapy using an emulsion of Lipiodol with doxorubicin,
in combination with stenting and long term systemic chemotherapy using mitozan-
trone, has been described in one case of cholangiocarcinoma19. The patient was
reported to be alive and well 27 months following diagnosis. Our own experience in
three cases treated with a Lipiodol-epirubicin emulsion has been disappointing,
with a mean survival of 5.4 months from the start of treatment12. Systemic
chemotherapy is rarely of benefit in cholangiocarcinoma, and whole liver irradia-
tion is dose-limited to a maximum of 3500 rads by the low tolerance of normal liver
tissue. However, the use of these modalities in combination with 131I Anti-CEA has
been reported to increase both response rates and survival2. It is possible that a
similar radical multimodal approach incorporating Lipiodol-targeted radiotherapy
may provide an effective means of palliation in some patients with cholangiocarci-
noma.
All fifteen patients with HCC showed tumour-specific retention of activity with
tumour: liver dose ratios of up to 30:1. Previous investigators have found
131I-Lipiodol to be retained almost exclusively by the liver and lungs3. A measure of
the accuracy of the dosimetry calculations used in this study can therefore be
obtained from comparison of tissue activities with the administered activity,
derived from the measured activity of the 31I-Lipiodol aliquot prior to injection
minus the residual activity the end of the procedure. Calculation of the combined
activities in tumour, liver and lung at time t 0 gave a median value of 87% of the
estimated administered activity, with a range of 70 118%. Taking into account
losses to other organs via the splanchnic circulation, and overestimation of the
administered activity due to adherence of activity to the syringe and catheter, this is
an acceptable accuracy for planar dosimetry. However, the accuracy of dosimetry
based on planar scintigraphy is inferior to that achievable using the more sophisti-
cated technique of SPECT imaging. For the last three cases in this series we had
access to a tomographic gamma camera, which acquires 60 images at intervals of 5
degrees rotation with an exposure time of 5 seconds 1 minute. By constructing a
tomographic gamma image this effectively eliminates errors from "background"
activity in surrounding tissues.
Partial tumour response was seen in two of three patients with Stage I tumours
(67%) and four of eleven patients with Stage II tumours (36%). There was no
significant difference in response rates between Stage I and II tumours (p 0.76,
Fisher exact probability test).
Patients showing response included one patient with fibrolamellar HCC. The
patient (No. 16), a 42 year old woman, presented with a massive tumour of the
right hepatic lobe invading the diaphragm, which had failed to respond to intra-RADIONUCLIDE LOCALISATION IN TUMOURS 197
Figure Ii Response in fibrolamellar HCC on CT scan. (a) At start of treatment (b) 20 months later.198 J.R. NOVELL ET AL.
arterial Lipiodol-epirubicin and systemic epirubicin treatment. Following
131I-Lipiodol therapy the tumour regressed to 20% of its original volume (Figure 6),
and the patient remains asymptomatic 19 months later. Spence et al.2 have
reported long term survival in a similar case treated by Lipiodol-targeted chemoth-
erapy; Lipiodol-targeted radiotherapy may also be effective in fibrolamellar HCC.
The mean survival in HCC was 7.1 (SD 6.0) months. Survival in Stage I was
better than in Stage II, although the number of patients with Stage I disease was
very small. The mean survival of patients showing partial response (11.6 months,
SD 6.8) was significantly better than that of patients with tumour progression or no
change (3.8 months, SD 1.7;p 0.004, pooled estimate of variance). This accords
with previous work on 131I brachytherapy: Order et a/.22, in an analysis ot the results
of targeted 131I antibody therapy in 343 patients, have demonstrated improved
survival in those patients whose tumours decreased in volume by more than 30% on
serial CT scanning. The cumulative survival rates of 61% at 6 months and 31% at 1
year in this series were identical to those obtained by Le Jeune et al.1, and similar
to the results of recent trials of Lipiodol-targeted chemotherapy23’24. The lower
toxicity of 13I-Lipiodol radiotherapy may make it the treatment of choice for small
(Stage I) tumours in older, cirrhotic patients who are at high risk of complications
following surgical resection.
Multiple treatments might be administered more easily via an infusion pump
than by repeated percutaneous cannulation as employed in this series. However,
external pumps are cumbersome and frequently complicated by thrombosis and
sepsis, whereas implantable systems are more convenient but are associated with a
significant local complication rate. Sclerosing cholangitis, chemical hepatitis, gastri-
tis and cholecystitis have all been reported25. The only treatment-related death in
this series resulted from sepsis and hepatorenal failure. The mean radiation dose to
the hepatic parenchyma for all cases was less than 4 Gy, and no evidence ot
hepatotoxicity was detected in the remaining patients. However, as a result of this
lethal complication we have modified our protocol and now give a smaller amount
of isotope in cirrhotic patients undergoing repeat treatments.
In summary, the results of 13-Lipiodol localisation in CCA were disappointing,
with evidence of tumour targeting in only one patient. However, the low toxicity of
131I-Lipiodol might justify its use as part of a regime combining several treatment
modalities. In HCC 131I-Lipiodol therapy has advantages over current non-surgical
therapies in terms of cytotoxic potential and low toxicity, resulting in objective
response in 40% ot patients. A good result was also observed in one patient with
fibrolamellar HCC. 3I-Lipiodol proved useful in patients with tumour recurrence
following surgery" it may also have a possible role in treating intrahepatic recur-
rences following orthotopic liver transplant. Caution is advocated in patients with
poor hepatic or renal function, particularly if treatments are repeated. We believe
that there is a need tor a larger randomised controlled study of this modality in
patients with Stage I and II HCC.
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INVITED COMMENTARY
Following Nakakuma and his colleagues surgical observations on the selective
retention of liver tumours1, there has been increasing interest in utilising this
"vehicle" for the delivery of both cytotoxic chemotherapy and radiotherapy. Initial
results have been promising in terms of tumour shrinkage and symptomatic
improvement but consistent survival data is lacking. This paper reports the
preliminary results of a small pilot study of 131-I lipiodol in both cholangiocarci-
noma and hepatocellular carcinoma.
There are several aspects which deserve comment. The method of delivery
employed is by percutaneous catheterisation of the femoral artery. Other groups,
including our own2, have preferred operative placement of the catheter with a
subcutaneous "port". This has the advantage of allowing repeated daily injections
so enabling fractionated doses to be given at repeated intervals. In addition it
reduces the rate of contamination and spillage of radioactive material. For example
if spillage occurred in the X-ray department this would inevitably mean closure of a
screening room for several weeks! In addition the risks of radioactive exposure to
staff using this technique is greater than with a closed system.
With regard to tumour assessment the ratios of tumour: liver depends very much
upon whether the liver region-of-interest was the liver or just a section of normal
liver. If it was the former then to dose ratios of tumour: liver seem very high when
judged by visual inspection of lipiodol images provided.
The lack of tumour-selective retention in cholangiocarcinoma is disappointing
especially in view of the favourable uptake in hepatocellular carcinoma. The major
effects however appear to be determined by the size of tumours. Multifocal small
deposits being the most avid retainers of radioactivity. It should be noted that this is
also a feature of liver metastases2. Clearly both pathological size and histology will
need to be taken into account in determining selection of suitable patients.
The authors have paid particular attention to adverse effects which is a major
consideration in phase I-II studies of this type. In general these are mild but
hepatotoxicity is a theoretical possibility and accurate placement of the catheter is
essential if gastritis and cholecystitis are to be avoided.
Overall this paper represents a valuable, albeit preliminary, evaluation of
lipiodol localisation in primary liver tumours and suggests that further work on this
novel treatment is justified.
Irving Taylor
Professor of Surgery and
Head of Department
University College
London
References
1. Nakakuma, K., Tashiro, S., Uemura, K. et al. (1979) An attempt for increasing effects of hepatic
artery ligation for advanced hepatoma (English abstract). Jap-Deutsche Med. Beriehte, 24,675-682
2. Hind, R.E., Loizidou, M., Perring, S., Fleming, J. and Batty, V. (1992) Biodistribution of lipiodol
following hepatic artery injection. Brit. J. Surg., 79, 952-954